Mesoblast Limited (MESO) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mesoblast Limited.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.475 I'm Silvio Tescu, I'm the Chief Executive of Miseblast. 00:00:04.475 -- 00:00:09.721 Together with me this morning is Marcella Santoro, our Chief Commercial 00:00:09.721 -- 00:00:14.606 Officer, and Andrew Schapanel, our Interim Chief Financial Officer. 00:00:14.606 -- 00:00:19.070 Today we're presenting our financial results and operational update for the half year 00:00:19.070 -- 00:00:23.613 ended December 31, 2024. We could 00:00:25.537 -- 00:00:27.599 go to 00:00:27.599 -- 00:00:30.299 slide four, please. 00:00:31.520 -- 00:00:37.848 Mesoblast is the global leader in allergenic cellular medicines for inflammatory diseases. 00:00:37.848 -- 00:00:42.433 We have one product already FDA approved, Rioncil. 00:00:42.433 -- 00:00:47.439 We have multiple locations globally. We're listed duly 00:00:47.439 -- 00:00:50.083 on the ASX and NASDAQ. 00:00:50.083 -- 00:00:55.209 We have more than 1,000 patents and patent applications 00:00:55.209 -- 00:00:58.293 that support our products. 00:00:58.293 -- 00:01:03.310 Beyond our first approved product, Rioncil, We have two other 00:01:03.310 -- 00:01:09.658 major products in phase three, and we have a whole pipeline sitting behind these. 00:01:09.658 -- 00:01:14.904 We have scalable manufacturing that have been FDA inspected, and we have a supply 00:01:14.904 -- 00:01:21.709 chain capability that allows us to meet the global needs commercially. 00:01:22.112 -- 00:01:24.452 Next slide, please. 00:01:24.535 -- 00:01:29.621 Our platform technology is based on a shared mechanism of action across all of our 00:01:29.621 -- 00:01:35.579 products. Our mesenchymal lineage precursor stromal cells 00:01:35.579 -- 00:01:38.383 are highly purified to 00:01:38.383 -- 00:01:44.092 very high concentrations i...